Overview
Clinical Meaning
The foundation of asthma management separates controller therapy (daily anti inflammatory agents) from reliever therapy (rescue bronchodilators).
PMHNP
PMHNP
The foundation of asthma management separates controller therapy (daily anti-inflammatory agents) from reliever therapy (rescue bronchodilators). ICS is the cornerstone controller reducing airway inflammation, hyperresponsiveness, and remodeling. GINA 2024 introduced a paradigm shift: anti-inflammatory reliever (AIR) therapy with low-dose ICS-formoterol PRN replaces SABA-only rescue across all steps. This ensures every reliever dose delivers anti-inflammatory therapy, reducing the dissociation between symptom relief and inflammation control. The as-needed ICS-formoterol approach reduces severe exacerbations by 60% compared to SABA-only reliever. For patients on traditional fixed-dose ICS, SABA remains the reliever, but SABA overuse (> 3 canisters/year) is a marker of poor control and increased mortality risk. The clinician must understand these distinctions to prescribe appropriately.
Unlock full lesson + practice questions
4 more sections with scenarios, priorities, and review drills.
Final rapid review before practice
Next study step
Finish the lesson first, then choose a focused activity to apply what you just reviewed.
Continue studying
Sign in to save progress on this lesson.
Unlock the interactive lesson quiz with a plan that includes this PMHNP pathway. You can still explore topic-filtered questions from the bank hubs below.